Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 4 months ago
Share
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
80 patients around the world
Available in
Spain, Argentina, United States
Neurocrine Biosciences
1
Research sites
80
Patients around the world
This study is for people with
Dyskinesia
Cerebral Palsy
Requirements for the patient
To 70 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
Sites
Instituto de Neurología Cognitiva (INECO)
Recruiting
Consult
View site
Marcelo Torcuato de Alvear 1632, C1021 Cdad. Autónoma de Buenos Aires, Argentina
View site
Consult
See details
Contact us
Contact us
Sponsor
Neurocrine Biosciences
Conditions
Requirements
To 70 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT05206513
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent